TGFB1 and autosomal dominant polycystic kidney disease: These data implied that the inhibitory effect of rosiglitazone on TGF-β1-stimulated ECM expression mainly operated through modulations of the SMAD pathway rather than the MAPK pathways in ADPKD cyst lining epithelial cells.